Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Parallel Study to Assess the Clinical Efficacy, Safety, and Tolerability of ViaDerm-hPTH [human parathyroid hormone] (1-34) in Comparison to Subcutaneous Injection of Forteo [teriparatide] in Postmenopausal Women With Osteoporosis and Osteopenia [bone resorption].

Next Previous
Trial Profile

A Multicenter, Randomized, Parallel Study to Assess the Clinical Efficacy, Safety, and Tolerability of ViaDerm-hPTH [human parathyroid hormone] (1-34) in Comparison to Subcutaneous Injection of Forteo [teriparatide] in Postmenopausal Women With Osteoporosis and Osteopenia [bone resorption].

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 08 May 2010 Results presented at 2010 IOF World Congress on Osteoporosis and 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
  • 01 Sep 2009 Primary endpoint 'change from baseline in procollagen 1 N-terminal propeptide (P1NP) levels at 96 days' has been met, as reported in a TransPharma Medical media release. Secondary efficacy and safety endpoints were also met.
  • 15 Jul 2009 Additional trial locations (Hungary, Czech Republic) added as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top